Drugs or medicines may be withdrawn from commercial markets because of risks to patients, but also because of commercial reasons (e.g. lack of demand and relatively high production costs). Where risks or harms is the reason for withdrawal, this will usually have been prompted by unexpected adverse effects that were not detected during Phase III clinical trials, i.e. they were only made apparent from postmarketing surveillance data collected from the wider community over longer periods of time.

202 drugs
Niclosan 500 mg

Niclosamide 500 mg

Yomesan 0.5 gm

Niclosamide 500 mg


Spectinomycin 2 mg


Halothane 99.9%

Halothane 99.9%

Halothane 99.9%

Avil 45.5mg/2ml

pheniramine 45.5mg

Avil 15mg/5ml

pheniramine 15mg

Avil 45.5mg

pheniramine 45.5mg

Avil retard 75mg

pheniramine 75mg

Acicone 540 mg/5 ml

Magaldrate 540 mg


Magaldrate 720 mg

Acicone S

Magaldrate 720 mg, Simethicone 25 mg